Kenichi Kobayashi1, Masahiro Seike2, Fenfei Zou1, Rintaro Noro1, Mika Chiba1, Arimi Ishikawa3, Shinobu Kunugi3, Kaoru Kubota1, Akihiko Gemma1. 1. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. 2. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan mseike@nms.ac.jp. 3. Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Abstract
BACKGROUND/AIM: Recent clinical trials have shown that immune checkpoint blockades that target either PD-1 or PD-L1 yield remarkable responses in a subgroup of patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We retrospectively examined, by immunohistochemical analysis, 211 NSCLC samples. Using 32 independent samples, we also evaluated PD-L1 expression in NSCLC patients with EGFR gene mutations treated by EGFR-TKIs. RESULTS: Overall survival of PD-L1-positive stages I-III NSCLC and stage I NSCLC and stages I-III squamous cell carcinoma (SQ) were significantly shorter than those of PD-L1-negative NSCLC (p<0.01 and p=0.02 and p=0.01, respectively). In stage I NSCLC and stages I-III SQ, PD-L1 expression was found to be independent predictor of death after multivariate analysis. Response to EGFR-TKIs was not significantly different between PD-L1-positive and PD-L1-negative NSCLC patients with EGFR mutations. CONCLUSION: PD-L1 expression was a significant independent predictor of poor outcome in NSCLC patients. Copyright
BACKGROUND/AIM: Recent clinical trials have shown that immune checkpoint blockades that target either PD-1 or PD-L1 yield remarkable responses in a subgroup of patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We retrospectively examined, by immunohistochemical analysis, 211 NSCLC samples. Using 32 independent samples, we also evaluated PD-L1 expression in NSCLCpatients with EGFR gene mutations treated by EGFR-TKIs. RESULTS: Overall survival of PD-L1-positive stages I-III NSCLC and stage I NSCLC and stages I-III squamous cell carcinoma (SQ) were significantly shorter than those of PD-L1-negative NSCLC (p<0.01 and p=0.02 and p=0.01, respectively). In stage I NSCLC and stages I-III SQ, PD-L1 expression was found to be independent predictor of death after multivariate analysis. Response to EGFR-TKIs was not significantly different between PD-L1-positive and PD-L1-negative NSCLCpatients with EGFR mutations. CONCLUSION:PD-L1 expression was a significant independent predictor of poor outcome in NSCLCpatients. Copyright
Authors: Yuchen Bai; Xiaoxia Chen; Likun Hou; Jun Qian; Tao Jiang; Caicun Zhou; Maciej Ciebiada Journal: Cancer Biol Med Date: 2018-11 Impact factor: 4.248
Authors: Stephanie Tuminello; Daniel Sikavi; Rajwanth Veluswamy; Cesar Gamarra; Wil Lieberman-Cribbin; Raja Flores; Emanuela Taioli Journal: Transl Lung Cancer Res Date: 2020-08